Discrimination of high-risk patients with rapid progression by Xi’an and other published criteria
ADVERSE EVENTS
Among the 71 patients with adverse outcome, 29/71 (41%) had an end-event within 2 years in the entire cohort. Next, we divided patients with adverse outcomes into 3 groups, including rapidly progressive (with adverse events within 2 years), moderately progressive (with adverse events from 2 to 5 years), slowly progressive patients (with adverse events over 5 years) both in training and validation cohort (Fig. Biochemical response according different criteria in patients with adverse outcomes over time in training cohort (